Trial Profile
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- A Phase 2 Subprotocol of Olaparib in Patients With Tumors Harboring Defects in DNA Damage Repair Genes
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Oct 2023
Price :
$35
*
At a glance
- Drugs Olaparib (Primary)
- Indications CNS cancer; Ependymoma; Ewing's sarcoma; Glioma; Histiocytosis; Langerhans cell histiocytosis; Liver cancer; Medulloblastoma; Neuroblastoma; Neuroectodermal tumours; Non-Hodgkin's lymphoma; Osteosarcoma; Rhabdoid tumour; Rhabdomyosarcoma; Soft tissue sarcoma; Solid tumours; Wilms' tumour
- Focus Therapeutic Use
- Acronyms Pediatric MATCH
- 26 Sep 2023 Planned End Date changed from 9 May 2024 to 22 Sep 2024.
- 11 May 2023 Planned End Date changed from 31 Mar 2024 to 9 May 2024.
- 23 Mar 2022 Planned End Date changed from 30 Sep 2024 to 31 Mar 2024.